Cathie Wood 在 CRISPR Therapeutics 投资 500 万美元,转而收购这些生物技术股票

周四,由 Cathie Wood 领导的 Ark Investment Management 出售了基因编辑公司 CRISPR Therapeutics AG (NASDA ......

Cathie Wood-led Ark Investment Management on Thursday sold 70,723 shares of gene editing company CRISPR Therapeutics AG (NASDAQ: CRSP), valued at over $5.58 million, via its flagship fund.

For ARK Innovation ETF (NYSE:ARKK), CRISPR is its fifth largest holding with a weight of 4.83%, according to holdings data on the firm’s website as of Thursday.

The flagship fund currently holds over 6 million shares in CRISPR valued at over $493 million. During the end of July, its CEO Samarth Kulkarni sold 25,000 shares, SEC filings showed.

Also Read: Alibaba Slips 1%, Nio, XPeng Rise Over 3%: Hang Seng Opens Firmer After Mixed Wall Street Session

Analyst Rating: Citigroup has increased the price target on the firm’s shares to $83, while maintaining a “neutral” rating, according to data from Benzinga Pro.

股票走势:该股周四收盘上涨 0.42%,至 78.91 美元。

其他交易:ARKK 购买了癌症诊断公司 EXACT Sciences Corporation(纳斯达克股票代码:EXAS)的 28,048 股股票,根据股票的最后收盘价计算,价值超过 138 万美元。EXACT Sciences 是该基金的第六大持股公司,权重为 4.66%。该股周四收盘上涨 3.72%。

该基金还购买了 113,483 股 Pacific Biosciences of California Inc (NASDAQ: PACB) 股票,截至周四收盘时价值超过 650,000 美元。

该基金目前持有该公司超过 1380 万股股票,价值超过 7200 万美元,权重为 0.71%。Pacific Biosciences 股价周四收盘上涨 11.52% 至 5.81 美元。

另请阅读:阿里巴巴下跌 1%,蔚来,小鹏上涨超过 3%:恒生在华尔街涨跌互现后开盘走强


Like this post? Please share to your friends:
Crypto Truth